NEW YORK (360Dx) – Accelerate Diagnostics announced today it has received CE-IVD marking for its Accelerate Pheno system targeting severe bacterial pneumonia infections.

According to the firm, researchers found that results for its severe pneumonia assay were available about 57 hours faster than normal standard of care.

Accelerate also announced that it expects to report fourth quarter revenue of $2.1 million, which would fall short of the consensus Wall Street estimate of $3.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.